COVID-19 Impact on Global Artemisinin Combination Therapy Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Artemisinin Combination Therapy Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Artemisinin Combination Therapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Artemether+Lumefantrine
  • 1.4.3 Artesunate+Amodiaquine
  • 1.4.4 Dihydroartemisinin+Piperaquine
  • 1.4.5 Artesunate+Mefloquine
  • 1.4.6 Artesunate+Sulfadoxine-Pyrimethamine
  • 1.4.7 Pyronaridine-Artesunate
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global Artemisinin Combination Therapy Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Artemisinin Combination Therapy Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Artemisinin Combination Therapy Industry
    • 1.6.1.1 Artemisinin Combination Therapy Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Artemisinin Combination Therapy Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Artemisinin Combination Therapy Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Artemisinin Combination Therapy Market Perspective (2015-2026)
• 2.2 Artemisinin Combination Therapy Growth Trends by Regions
  • 2.2.1 Artemisinin Combination Therapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Artemisinin Combination Therapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Artemisinin Combination Therapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Artemisinin Combination Therapy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Artemisinin Combination Therapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Artemisinin Combination Therapy Players by Market Size
  • 3.1.1 Global Top Artemisinin Combination Therapy Players by Revenue (2015-2020)
  • 3.1.2 Global Artemisinin Combination Therapy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Artemisinin Combination Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Artemisinin Combination Therapy Market Concentration Ratio
  • 3.2.1 Global Artemisinin Combination Therapy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Artemisinin Combination Therapy Revenue in 2019
• 3.3 Artemisinin Combination Therapy Key Players Head office and Area Served
• 3.4 Key Players Artemisinin Combination Therapy Product Solution and Service
• 3.5 Date of Enter into Artemisinin Combination Therapy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Artemisinin Combination Therapy Historic Market Size by Type (2015-2020)
• 4.2 Global Artemisinin Combination Therapy Forecasted Market Size by Type (2021-2026)

5 Artemisinin Combination Therapy Breakdown Data by Application (2015-2026)

• 5.1 Global Artemisinin Combination Therapy Market Size by Application (2015-2020)
• 5.2 Global Artemisinin Combination Therapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Artemisinin Combination Therapy Market Size (2015-2020)
• 6.2 Artemisinin Combination Therapy Key Players in North America (2019-2020)
• 6.3 North America Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 6.4 North America Artemisinin Combination Therapy Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Artemisinin Combination Therapy Market Size (2015-2020)
• 7.2 Artemisinin Combination Therapy Key Players in Europe (2019-2020)
• 7.3 Europe Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 7.4 Europe Artemisinin Combination Therapy Market Size by Application (2015-2020)

8 China

• 8.1 China Artemisinin Combination Therapy Market Size (2015-2020)
• 8.2 Artemisinin Combination Therapy Key Players in China (2019-2020)
• 8.3 China Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 8.4 China Artemisinin Combination Therapy Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Artemisinin Combination Therapy Market Size (2015-2020)
• 9.2 Artemisinin Combination Therapy Key Players in Japan (2019-2020)
• 9.3 Japan Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 9.4 Japan Artemisinin Combination Therapy Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Artemisinin Combination Therapy Market Size (2015-2020)
• 10.2 Artemisinin Combination Therapy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 10.4 Southeast Asia Artemisinin Combination Therapy Market Size by Application (2015-2020)

11 India

• 11.1 India Artemisinin Combination Therapy Market Size (2015-2020)
• 11.2 Artemisinin Combination Therapy Key Players in India (2019-2020)
• 11.3 India Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 11.4 India Artemisinin Combination Therapy Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Artemisinin Combination Therapy Market Size (2015-2020)
• 12.2 Artemisinin Combination Therapy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Artemisinin Combination Therapy Market Size by Type (2015-2020)
• 12.4 Central & South America Artemisinin Combination Therapy Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 KPC Pharmaceuticals
  • 13.1.1 KPC Pharmaceuticals Company Details
  • 13.1.2 KPC Pharmaceuticals Business Overview and Its Total Revenue
  • 13.1.3 KPC Pharmaceuticals Artemisinin Combination Therapy Introduction
  • 13.1.4 KPC Pharmaceuticals Revenue in Artemisinin Combination Therapy Business (2015-2020))
  • 13.1.5 KPC Pharmaceuticals Recent Development
• 13.2 Shanghai Fosun Pharmaceutical Industrial Development
  • 13.2.1 Shanghai Fosun Pharmaceutical Industrial Development Company Details
  • 13.2.2 Shanghai Fosun Pharmaceutical Industrial Development Business Overview and Its Total Revenue
  • 13.2.3 Shanghai Fosun Pharmaceutical Industrial Development Artemisinin Combination Therapy Introduction
  • 13.2.4 Shanghai Fosun Pharmaceutical Industrial Development Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.2.5 Shanghai Fosun Pharmaceutical Industrial Development Recent Development
• 13.3 Sanofi
  • 13.3.1 Sanofi Company Details
  • 13.3.2 Sanofi Business Overview and Its Total Revenue
  • 13.3.3 Sanofi Artemisinin Combination Therapy Introduction
  • 13.3.4 Sanofi Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.3.5 Sanofi Recent Development
• 13.4 Desano Holdings
  • 13.4.1 Desano Holdings Company Details
  • 13.4.2 Desano Holdings Business Overview and Its Total Revenue
  • 13.4.3 Desano Holdings Artemisinin Combination Therapy Introduction
  • 13.4.4 Desano Holdings Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.4.5 Desano Holdings Recent Development
• 13.5 Calyx Chemicals and Pharmaceuticals
  • 13.5.1 Calyx Chemicals and Pharmaceuticals Company Details
  • 13.5.2 Calyx Chemicals and Pharmaceuticals Business Overview and Its Total Revenue
  • 13.5.3 Calyx Chemicals and Pharmaceuticals Artemisinin Combination Therapy Introduction
  • 13.5.4 Calyx Chemicals and Pharmaceuticals Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.5.5 Calyx Chemicals and Pharmaceuticals Recent Development
• 13.6 Mylan
  • 13.6.1 Mylan Company Details
  • 13.6.2 Mylan Business Overview and Its Total Revenue
  • 13.6.3 Mylan Artemisinin Combination Therapy Introduction
  • 13.6.4 Mylan Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.6.5 Mylan Recent Development
• 13.7 Novartis
  • 13.7.1 Novartis Company Details
  • 13.7.2 Novartis Business Overview and Its Total Revenue
  • 13.7.3 Novartis Artemisinin Combination Therapy Introduction
  • 13.7.4 Novartis Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.7.5 Novartis Recent Development
• 13.8 Denk Pharma
  • 13.8.1 Denk Pharma Company Details
  • 13.8.2 Denk Pharma Business Overview and Its Total Revenue
  • 13.8.3 Denk Pharma Artemisinin Combination Therapy Introduction
  • 13.8.4 Denk Pharma Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.8.5 Denk Pharma Recent Development
• 13.9 Hovid Berhad
  • 13.9.1 Hovid Berhad Company Details
  • 13.9.2 Hovid Berhad Business Overview and Its Total Revenue
  • 13.9.3 Hovid Berhad Artemisinin Combination Therapy Introduction
  • 13.9.4 Hovid Berhad Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.9.5 Hovid Berhad Recent Development
• 13.10 Ipca Laboratories
  • 13.10.1 Ipca Laboratories Company Details
  • 13.10.2 Ipca Laboratories Business Overview and Its Total Revenue
  • 13.10.3 Ipca Laboratories Artemisinin Combination Therapy Introduction
  • 13.10.4 Ipca Laboratories Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 13.10.5 Ipca Laboratories Recent Development
• 13.11 Cipla
  • 10.11.1 Cipla Company Details
  • 10.11.2 Cipla Business Overview and Its Total Revenue
  • 10.11.3 Cipla Artemisinin Combination Therapy Introduction
  • 10.11.4 Cipla Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 10.11.5 Cipla Recent Development
• 13.12 Aspen Pharmacare Holdings
  • 10.12.1 Aspen Pharmacare Holdings Company Details
  • 10.12.2 Aspen Pharmacare Holdings Business Overview and Its Total Revenue
  • 10.12.3 Aspen Pharmacare Holdings Artemisinin Combination Therapy Introduction
  • 10.12.4 Aspen Pharmacare Holdings Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 10.12.5 Aspen Pharmacare Holdings Recent Development
• 13.13 Ajanta Pharma
  • 10.13.1 Ajanta Pharma Company Details
  • 10.13.2 Ajanta Pharma Business Overview and Its Total Revenue
  • 10.13.3 Ajanta Pharma Artemisinin Combination Therapy Introduction
  • 10.13.4 Ajanta Pharma Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 10.13.5 Ajanta Pharma Recent Development
• 13.14 Guilin Pharmaceuticals
  • 10.14.1 Guilin Pharmaceuticals Company Details
  • 10.14.2 Guilin Pharmaceuticals Business Overview and Its Total Revenue
  • 10.14.3 Guilin Pharmaceuticals Artemisinin Combination Therapy Introduction
  • 10.14.4 Guilin Pharmaceuticals Revenue in Artemisinin Combination Therapy Business (2015-2020)
  • 10.14.5 Guilin Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer